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Abstract
Background: Bicuspid aortic valve (BAV) disease is the most common congenital cardiac abnormality affecting
1–2% of the population and is associated with a significantly increased risk of ascending aortic aneurysm.
However, predicting which patients will develop aneurysms remains a challenge. This pilot study aimed to
identify candidate plasma biomarkers for monitoring ascending aortic diameter and predicting risk of future
aneurysm in BAV patients.
Methods: Plasma samples were collected pre-operatively from BAV patients undergoing aortic valve surgery.
Maximum ascending aortic diameter was measured on pre-operative transoesophageal echocardiography.
Maximum diameter ≥ 45 mm was classified as aneurysmal. Sequential Window Acquisition of all THeoretical
Mass Spectra (SWATH-MS), an advanced mass spectrometry technique, was used to identify and quantify all
proteins within the samples. Protein abundance and aortic diameter were correlated using logistic regression.
Levene’s test was used to identify proteins demonstrating low abundance variability in the aneurysmal
patients (consistent expression in disease), and high variability in the non-aneurysmal patients (differential
expression between ‘at risk’ and not ‘at risk’ patients).
Results: Fifteen plasma samples were collected (seven non-aneurysmal and 8 aneurysmal BAV patients). The mean age
of the patients was 55.5 years and the majority were female (10/15, 67%). Four proteins (haemoglobin subunits alpha,
beta and delta and mannan-binding lectin serine protease) correlated significantly with maximal ascending aortic
diameter (p < 0.05, r = 0.5–0.6). Five plasma proteins demonstrated significantly lower variability in the aneurysmal group
and may indicate increased risk of aneurysm in non-aneurysmal patients (DNA-dependent protein kinase catalytic subunit,
lumican, tetranectin, gelsolin and cartilage acidic protein 1). A further 7 proteins were identified only in the aneurysmal
group (matrin-3, glucose-6-phosphate isomerase, coactosin-like protein, peptidyl-prolyl cis-trans isomerase A, golgin
subfamily B member 1, myeloperoxidase and 2′-deoxynucleoside 5′-phosphate N-hydrolase 1).
Conclusions: This study is the first to identify candidate plasma biomarkers for predicting aortic diameter and risk of
future aneurysm in BAV patients. It provides valuable pilot data and proof of principle that could be used to design a
large-scale prospective investigation. Ultimately, a more affordable ‘off-the-shelf’ follow-on blood assay could then be
developed in place of SWATH-MS, for use in the healthcare setting.
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Background
Bicuspid aortic valve (BAV) disease is the most common
congenital cardiac malformation affecting 1–2% of the
population [1, 2]. BAV occurs when the aortic valve
forms with just two leaflets (or cusps), rather than the
normal three (tricuspid aortic valve; TAV). Although be-
tween 30 and 80% of patients with BAV disease will de-
velop clinically significant enlargement of the ascending
aorta, predictors of aortic dilation are lacking [3, 4]. The
consequences of undiagnosed or rapidly progressive
aneurysm can be severe, with rupture and dissection fre-
quently being fatal. There is ongoing controversy regard-
ing optimal timing of ascending aortic surgery for
patients with BAV disease [5, 6]. Current guidelines are
limited to measurement of ascending aortic diameter
and the extent of aortic valve disease when planning sur-
gery for aortic aneurysm in BAV patients [7]. An ability
to predict which BAV patients will develop ascending
aortic aneurysm would allow better individualisation of
treatment and help prevent the potentially catastrophic
complications of rupture and dissection.
A biomarker may be defined as a measurable gene, pro-
tein, cell or metabolic by-product that represents a process
in a defined biological system or disease state [8, 9]. One
or a combination of biomarkers may be measured to give
information about risk, presence and progress of a par-
ticular disease. Several studies have attempted to iden-
tify biomarkers in BAV aortopathy, however few have
investigated blood biomarkers. Matrix metalloprotein-
ases (MMPs) are implicated in the pathogenesis of
BAV aortopathy, and the expression of MMP-2,
MMP-8 and MMP-9 has been demonstrated to cor-
relate with ascending aortic diameter [10–14]. Simi-
larly, asymmetric dimethylarginine (ADMA; a nitric
oxide synthase inhibitor), alpha-1-antitrypsin (α1AT;
an abundant protease inhibitor) and more recently
circulating endothelial microparticles (EMP), have all been
shown to differ in expression between non-aneurysmal
and aneurysmal BAV patients [12, 13, 15]. Currently how-
ever, measurement of the ascending aortic diameter is the
only method widely used to monitor aortopathy in BAV
patients [16].
Sequential Window Acquisition of all THeoretical Mass
Spectra (SWATH-MS) is one of the most recent advances
in protein quantification technology, combining the ad-
vantages of the shotgun (high throughput) and selected
reaction monitoring (high reproducibility and consistency)
mass spectrometry techniques [17]. In essence, it allows a
complete recording of all fragment ions of the detectable
peptide precursors present in a biological sample, and
thus is ideally suited to biomarker discovery. However, to
the best of our knowledge, the technique has never before
been used for the purpose of biomarker discovery in
BAV-associated aneurysms.
Discovery of novel biomarkers for detection and moni-
toring of aneurysms in BAV disease has a number of po-
tential benefits. Firstly, a suitable biomarker could be
monitored as an indicator of aortic diameter in prefer-
ence to repeated imaging, particularly computerised
tomography, which carries a radiation risk. Secondly,
biomarkers that predict risk of future aneurysm in BAV
patients would help prevent catastrophic complications
and allow individualisation when planning aortic sur-
gery. The question asked recently by Sievers et al. is ex-
tremely important; in the young patient requiring aortic
valve replacement for severe aortic stenosis, with an as-
cending aortic diameter at the higher end of normal;
should it be replaced? [18] There is a pressing need for
biomarkers to facilitate a more patient-centred approach
to managing BAV aortopathy. We hypothesise that a
subpopulation of BAV patients without aortic aneurysms
exhibit a biomarker profile that indicates they will de-
velop ascending aortic aneurysm in future. Therefore,
the two aims of this study were to correlate plasma pro-
tein concentrations with ascending aortic diameter to
identify biomarkers which could be used to estimate as-
cending aortic diameter in BAV patients. Secondly, to
identify biomarkers which are homogenously expressed
in the aneurysmal BAV group but differentially expressed
in non-aneurysmal BAV patients, and may signify in-
creased risk of future aneurysm. Here we show that a
number of candidate predictors for aortic diameter were
identified and these may help stratify the future risk of
aneurysm in BAV patients. Our study, albeit small, pro-
vides proof of principle data that offers confidence in the
potential design of a larger, prospective investigation of
candidate BAV biomarkers.
Methods
Ethical approval and sample collection
This study complied with the declaration of Helsinki.
Ethical approval was granted by Hampshire B NRES
committee south central (REC Ref: 11/SC/0258). The
local sponsor was University Hospital Southampton
R&D Department (Protocol Ref: RHM CAR 0392). In-
formed consent was obtained from patients admitted
electively to the University Hospital Southampton, UK
for aortic valve replacement and/or ascending aortic re-
placement. Patients with mitral valve disease (greater
than mild), atherosclerosis of the ascending aorta (either
on pre-operative imaging or observed intraoperatively),
infective endocarditis, known genetic conditions (such
as Marfan Syndrome), and those aged under 18 or over
80 were excluded from the study. Demographic informa-
tion, past medical history, echocardiography data and
blood results were collected. In the anaesthetic room, all
patients underwent transoesophageal echocardiography
(TOE) as part of the routine theatre practice. From these
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images, ascending aortic measurements were obtained.
Aneurysm of the ascending aorta was defined as diam-
eter ≥ 45 mm. Aortic valve morphology was defined in-
traoperatively by the surgeon according to the Sievers
classification [19]. Fifteen plasma samples were collected
(seven from non-aneurysmal and 8 from aneurysmal
BAV patients). Shortly after the induction of anaesthesia
4 mL of whole blood was taken from the central venous
cannula immediately after insertion. The blood was col-
lected following our standard operating procedure (SOP)
in an EDTA containing tube and immediately placed on
ice before being centrifuged at 1500 rpm for 10 min at
4o C. The plasma layer was aliquoted into microtubes
and stored at -80o C until use.
Plasma samples were subject to SWATH-MS ac-
cording to the standard operating procedures of the
Stoller Biomarker Discovery Centre, Manchester, UK
(see Additional file 1). In brief, major plasma proteins
were removed by immunodepletion following which
protein concentration was measured in each sample.
Samples were then digested and dried overnight before
processing in a SCIEX TripleTOF 6600 variable window
mass spectrometer with a 120 min run time. The presence
and abundance of plasma proteins was quantified using
protein spectral libraries and SWATH-MS maps.
Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics (Version 22.0). Linear regression analysis was per-
formed to detect significant correlations between
maximum aortic diameter and plasma protein levels.
Levene’s test was used to identify plasma proteins dem-
onstrating significant differences in equality of variance
between non-aneurysmal and aneurysmal groups.
Levene’s test assesses the probability that a difference in
the variability between two populations has occurred by
chance. Where Levene’s test was significantly different,
scatter plots were generated and proteins displaying low
variability in the aneurysmal group (and high variability in
the non-aneurysmal group) were identified as potential
aortopathy risk predictors. An ‘at risk’ cut-off point for can-
didate biomarker expression in the non-aneurysmal patients
was established at 2 standard deviations above or below the
mean expression in the aneurysmal group. Where candidate
markers were expressed in non-aneurysmal patients at such
a level, these patients were deemed hypothetically ‘at risk’.
p < 0.05 was taken as statistically significant.
Results
Fifteen plasma samples were collected (seven non-
aneurysmal and eight aneurysmal BAV patients). The
mean age of the patients was 55.5 years and the majority
of patients were female (10/15; 67%, Table 1). The
groups were equally matched, except none of the
aneurysmal patients were prescribed statins and their
pre-operative haemoglobin values were higher. Overall
826 proteins were identified across the 15 samples.
Plasma biomarkers as predictors of aortic diameter in
BAV patients
Linear regression analysis of plasma proteins revealed
four significant (p < 0.05) predictors of maximum aortic
diameter in BAV patients (Table 2). Haemoglobin
subunits alpha, beta and delta correlated positively
with increasing maximum ascending aortic diameter,
and Mannan-binding lectin serine protease correlated
negatively (Fig. 1). All four proteins demonstrated
moderate correlation (r = 0.5 to 0.6). Of note, the pa-
tient’s pre-operative serum haemoglobin did not cor-
relate significantly with the maximum aortic diameter
(p = 0.279).
Plasma biomarkers to predict risk of future aortopathy
In order to identify potential plasma protein biomarkers
predictive of future aneurysm risk, subgroup analysis
was performed on the BAV non-aneurysmal group. Five
candidate plasma protein markers exhibiting low vari-
ance in the aneurysmal group but high variance in the
non-aneurysmal group were identified as potential pre-
dictors of future aortopathy (Fig. 2). These were
DNA-dependent protein kinase catalytic subunit, lumi-
can, tetranectin, gelsolin and cartilage acidic protein 1.
In addition, seven proteins were identified in the
plasma from all patients with aneurysmal aortas but only
identified in a subset of the non-aneurysmal group.
These were matrin-3, glucose-6-phosphate isomerase,
coactosin-like protein, peptidyl-prolyl cis-trans isomerase
A, golgin subfamily B member 1, myeloperoxidase and
2′-deoxynucleoside 5′-phosphate N-hydrolase 1. Table 3
summarises the plasma proteins implicated above.
Discussion
The two main findings of this study are that four plasma
proteins were identified as potential biomarkers for
monitoring maximum aortic diameter in BAV patients,
and 12 plasma proteins were identified as potential indi-
cators for future aneurysm risk in BAV patients with
non-aneurysmal aortas.
The advantage of SWATH-MS is that all proteins
within a plasma sample can be detected and quantified,
raising the possibility of discovering previously unknown
relationships between these biomarkers and ascending
aortic diameter in BAV patients. This study identified
four unique plasma biomarkers that correlated signifi-
cantly with maximum ascending aortic diameter in BAV
patients. Previous studies have identified plasma bio-
markers that correlate with aortic dimension in BAV dis-
ease. Tzemos et al. found MMP-2 levels correlated
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significantly with ascending aortic diameter, findings that
are supported by the more recent work of Wang et al.
[11, 14]. However, Abaci et al. found no correlation be-
tween MMP-2 and ascending aortic diameter [20]. In
the present study, MMP-9 and 14 were elevated in the
order of 11 and 41% respectively in the aneurysmal
group but this was not statistically significant (p = 0.767
and p = 0.242 respectively). Drapisz et al. found a posi-
tive correlation between ADMA (eNOS inhibitor) and
aortic annulus diameter (r = 0.4, p = 0.043) and Kilickesmez
et al. demonstrated a significantly negative correlation be-
tween ascending aortic diameter and α1-antitrypsin level
(r = − 0.300, p = 0.006) [12, 13].
In this study, haemoglobin subunits alpha, beta and
delta were found to correlate significantly with ascend-
ing aortic diameter in BAV patients. In adults, two alpha
and two beta subunits combine to form one haemoglo-
bin A molecule (HbA), which comprises approximately
97% of circulating haemoglobin. Combination of two
alpha and two delta subunits forms haemoglobin A2,
which together with fetal haemoglobin (HbF) makes up
the remaining 3% of circulating haemoglobin [21]. Sup-
porting these findings pre-operative serum haemoglobin
(Hb) was significantly increased in the aneurysmal group
versus non-aneurysmal but did not correlate significantly
with maximum aortic diameter. This is a novel observa-
tion as to the best of our knowledge, there are no previ-
ous reports of this association in the literature. In
abdominal aortic aneurysms (AAA) however, trapping of
Table 2 Significant predictors of maximum aortic diameter in
BAV patients
Plasma Protein Pearson
coefficient (r)
P-value Gradient
(m)
y-intercept
(c)
Haemoglobin
subunit beta
0.576 0.025 0.410 0.066
Haemoglobin
subunit delta
0.558 0.030 0.670 −2.552
Haemoglobin
subunit alpha
0.547 0.035 0.339 1.119
Mannan-binding
lectin serine
protease 1
−0.552 0.033 −0.679 11.745
Table 1 Patient demographics
Demographic Non-aneurysmal
(n = 7)
Aneurysmal
(n = 8)
p-value
Mean age (years) 59.3 ± 13.3 51.8 ± 10.4 0.24
Gender (n) 0.32
Male 3 2
Female 4 6
Mean body mass
index (kg/m2)
29.9 ± 5.0 29.7 ± 5.1 0.92
Mean maximum ascending
aortic diameter (mm)
40.6 ± 2.6 53.4 ± 5 < 0.001
Mean blood pressure (mmHg)
Systolic 137 ± 15.6 133 ± 16.3 0.61
Diastolic 73 ± 10.4 76 ± 11.1 0.57
Smoking status (n) 0.35
Non-smoker 5 3
Ex-smoker 2 4
Current smoker 0 1
Type 2 diabetes (n) 2 1 0.57
Medications (n patients taking)
ACE inhibitor 2 1 0.57
β-blocker 3 2 0.61
Angiotensin Receptor
Blocker
1 0 0.47
Calcium Channel Blocker 1 0 0.47
Statin 4 0 0.03
Aortic valve disease (n) 0.33
Normal 0 0
Stenosis 3 1
Mild 0 0
Mod 0 0
Severe 5 6
Regurgitation 2 2
Mild 1 3
Mod 1 1
Severe 2 3
Mixed 2 5
Left ventricular ejection
fraction (n)
0.47
45–70% 7 6
35–44% 0 0
< 35% 0 0
Unknown 0 2
Mean preoperative blood results
Haemoglobin (g/dl) 138 ± 15 155 ± 15 0.047
White cell count (× 109/l) 6.9 ± 1.8 8.7 ± 2.9 0.17
Platelet count (×109/l) 226 ± 38 235 ± 38 0.65
Urea (mmol/l) 5.1 ± 1.6 4.7 ± 1.1 0.58
Table 1 Patient demographics (Continued)
Demographic Non-aneurysmal
(n = 7)
Aneurysmal
(n = 8)
p-value
Creatinine (μmol/l) 85 ± 28 76 ± 23 0.50
C-reactive protein
(CRP; mg/l)
4.0 ± 2.2 4.9 ± 4.1 0.71
Serum cholesterol (mmol/L) 5.4 ± 0.9 5.3 ± 0.5 0.84
Mean values are given ± standard deviation. P-values are given for
independent samples t-tests between the study groups. Significant p-values
(p < 0.05) are highlighted in bold
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erythrocytes within areas of intraluminal thrombus may
lead to haemolysis and subsequent release of Hb, heme
and iron, which liberates reactive oxygen species (ROS)
[22]. Erythrocytes and heme deposits are also phagocy-
tosed by immune cells in the aortic wall [23]. Neverthe-
less, intraluminal thrombus is not commonly associated
with BAV ascending aortic aneurysms and inflammation
is classically absent [24, 25]. The lack of any previous re-
ports of these observations requires further investigation
and validation in a larger patient cohort.
A major goal in the treatment of BAV aortopathy is
developing a method of predicting which patients will
develop aneurysms. To date, only one study has
attempted to do this by subdividing BAV patients with
non-aneurysmal aortas based on risk of future aortopa-
thy but using aortic tissue samples instead of blood bio-
markers. Grewal et al. quantified an array of cellular
markers in ascending aortic tissue samples from
aneurysmal and non-aneurysmal BAV and TAV patients
[26]. TGF-β and pSmad2 (markers of vascular remodel-
ling) were significantly reduced in a proportion of the
non-aneurysmal BAV group versus the other non-
aneurysmal patients and the aneurysmal BAV group.
The study concluded that a subgroup of BAV patients
with non-aneurysmal aortas appear to have more active
remodelling than others, which could represent suscepti-
bility to developing aneurysm. To our knowledge, the
paper by Grewal et al. is the first to attempt to subdivide
non-aneurysmal BAV patients on the basis of suscepti-
bility to developing aneurysm using biomarkers. Whilst
it did not employ a plasma biomarker, which would be
more practical in clinical practice, it set precedence for
the future direction in detecting and preventing BAV
aortopathy in susceptible individuals.
The present study is the first to utilise SWATH-MS to
quantify all detectable proteins in blood plasma samples
and identify potential biomarkers which may predict ‘at
risk’ non-aneurysmal BAV patients. The principle advan-
tage of blood over a tissue biomarker is that plasma
samples are more easily obtainable, in comparison to as-
cending aortic tissue, which is less practical. Therefore, a
result can be obtained from a blood test and a treatment
plan implemented long before aneurysm develops.
Twelve potential plasma biomarkers were identified. Of
note, the ‘at risk’ patients demonstrated increased
DNA-dependent protein kinase catalytic subunit, a pro-
tein associated with DNA damage, which may reflect the
increased remodelling and vascular smooth muscle cell
(VSMC) apoptosis occurring in BAV aortopathy. Similarly,
down regulation of two key extracellular matrix (ECM)
and VSMC cytoskeletal assembly proteins lumican and
gelsolin were also observed in the ‘at risk’ profile. This is
concurrent with accelerated ECM degradation and VSMC
loss observed in BAV aortopathy [27, 28]. Therefore, these
Fig. 1 Scatter plots displaying the significant relationships between four plasma proteins and maximum aortic diameter in BAV patients (n = 15).
Protein expressions are log2 values of SWATH-MS abundance
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biomarkers may reflect underlying pathological processes
occurring in the ascending aorta and could represent en-
tities with which to predict future aortopathy in BAV pa-
tients. A summary diagram of the key findings of this
study can be found in Fig. 3.
A major limitation of this pilot study was not valid-
ating candidate biomarkers through follow-up of
changes in ascending aortic diameter of the
non-aneurysmal patients over time. This was not pos-
sible within the time scale of this study but should be
included in the design of a future prospective valid-
ation investigation. Furthermore, in concluding that
our candidate biomarkers may predict future
aneurysm based on similar expression to aneurysmal
patients, our assumption was that expression of the
biomarkers remains constant. However, we cannot ex-
clude the possibility that expression may vary over
time and a validation study is required to confirm ex-
pression stability. Another limitation of this study was
the small sample size. The main reason for this is the
time taken to perform detailed informatics analysis of
the data generated is considerable, therefore large
sample numbers were not feasible within the time
scale of this study. With small sample numbers, we
cannot exclude the possibility that differences in the
patient’s demographics (e.g. statin use and valve
morphology) may have influenced the differences in
protein expression described in this study. Further-
more, we were unable to correlate the plasma find-
ings in paired tissue samples, although this is a
subject of ongoing investigation. In addition, TAV
control groups would have proved useful to ensure
that the proteins identified were indeed unique to
BAV aortopathy. However, investigation of TAV
Fig. 2 Scatter plots of candidate plasma biomarkers for predicting risk of aortopathy in non-aneurysmal BAV patients. Horizontal lines at 4.5 cm
indicate the study’s division between non-aneurysmal and aneurysmal ascending aortic diameter. Vertical lines indicate mean expression in the
aneurysmal group ± 2 standard deviations. Blue area = aneurysmal BAV cohort expressions upto mean ± 2 standard deviation; red area =
hypothetically ‘at risk’ non-aneurysmal BAV patients; and green area = hypothetically not ‘at risk’ non-aneurysmal patients. Protein expression is
given as log2 SWATH-MS abundance
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aneurysms was not the focus of this study, and the
biomarkers identified may still differentiate ‘at risk’
BAV patients regardless of their presence in TAV pa-
tients. Finally, this study did not use correction for
multiple testing, despite identifying a large number of
candidate biomarkers. Whilst this has the potential to
introduce falsely positive biomarkers, the priority of
this study was to identify of all potential biomarkers
for future investigation, rather than excluding those
with lower potential value.
Table 3 Candidate plasma biomarkers for predicting risk of aneurysm in BAV patients with non-aneurysmal aortas
Protein Name Uniprot ID Function Up- or
downregulateda
DNA-dependent protein
kinase catalytic subunit
P78527 Serine/threonine-protein kinase, molecular sensor for DNA damage. Up
Lumican P51884 Collagen fibril organization, epithelial cell migration and tissue repair. Down
Tetranectin P05452 Binds plasminogen and isolated kringle 4.
Packaging molecules for exocytosis.
Down
Gelsolin P06396 Key regulator of actin filament assembly and disassembly. Down
Cartilage acidic protein 1 Q9NQ79 Upregulated by BMP4 in mesenchymal stem cells undergoing
chondrogenic differentiation.
Down
Matrin-3 P43243 Transcription and interaction with other nuclear matrix
proteins to form the internal fibrogranular network.
N/A
Glucose-6-phosphate
isomerase
P06744 Glycolytic enzyme and angiogenic factor (AMF)
that stimulates endothelial cell motility.
N/A
Coactosin-like protein Q14019 Binds to F-actin in a calcium-independent manner. N/A
Peptidyl-prolyl cis-trans
isomerase A
P62937 Accelerates the folding of proteins. N/A
Myeloperoxidase P05164 Produces hypochlorous acid (HOCl) used by the neutrophils to kill
bacteria and other pathogens.
N/A
Golgin subfamily B
member 1
Q14789 Forms intercisternal cross-bridges of the Golgi complex. N/A
2′-deoxynucleoside
5′-phosphate N-hydrolase 1
O43598 Catalyses cleavage of the N-glycosidic bond of
deoxyribonucleoside 5′-monophosphates.
N/A
Biomarker name, Uniprot ID, function and direction of change are given
aDirection of change in plasma biomarker that indicates a patient may be at risk of future aortopathy. ‘N/A’ (not applicable) indicates that presence of the protein
in plasma alone may indicate risk of future aortopathy
Fig. 3 Summary diagram of the key findings in this study. Red dots represent plasma biomarkers which may be associated with an increased risk
of aneurysm formation (red box). Blue dots represent plasma biomarkers which predict aneurysm diameter (blue box)
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Conclusions
This study identified a number of candidate predictors
for aortic diameter and future risk of aneurysm in BAV
patients. It provides valuable data and proof of principle
that could be used to design a large scale prospective in-
vestigation of several hundred BAV patients. Plasma
levels of candidate biomarkers need to be quantified in a
large population of BAV patients and matched with
changes in ascending aortic diameter from serial
follow-up imaging, allowing direct correlation with dis-
ease progression. Ultimately, a more affordable ‘off-the--
shelf ’ follow-on blood assay could then be developed in
place of SWATH-MS for use in the healthcare setting.
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